National and Kapodistrian University of Athens
Μελέτη γονιδιακών διαταραχών στο καρκίνωμα του θυρεοειδούς στην Ελλάδα
Abstract
dc:descriptionThe MAP kinase (RAS/RAF/MEK/ERK) signaling pathway is directly implicated in the modulation of the Thyroid cancer. In the present study we investigated the molecular genetics of this signaling pathway in Greek patients with follicular cell origin thyroid carcinoma. In addition, an attempt was made to relate the presence, if any, of genetic alterations with the diagnosis and prognosis of Thyroid cancer. Our material constituted 100 paraffin blocks from the files of the 1st Department of Pathology, Medical School, University of Athens, Greece, as well as, 26 fresh tissues taken directly from thyroid carcinomas. Paraffin sections were prepared from the paraffin blocks, in order to perform DNA extraction and immunohistochemistry. DNA and RNA were also extracted from the fresh tissue. In addition, 13 thyroid cancer cell lines were used comparatively. The presence of the RET/PTC 1,2,3 rearrangements, as well as the presence of BRAF, EGFR, MET and NTRK 1,2,3 mutations was detected with the use of PCR, RT-PCR, Southern Blotting, and Direct Sequencing. The phenotypic evaluation was performed with the immunohistochemical study of phospho-MET, phospho-EGFR, BRAF, MEK, phospho-MEK, ERK, and phospho-ERK. RET/PTC 2,3 rearrangements were detected in 7,7%, were as BRAFV600E mutation in 26,5%. No association was detected between the presence of BRAFV600E mutation and the four parameters studied (age and sex of the patients, the disease stage, and the prognostic groups). In addition, 2 new point mutations (S695G and V834M) (2,9%) and 4 silent mutations (15,9%) were detected in the egfr gene. The study of the met gene revealed only a silent mutation in 84,4%. The immunohistochemical study revealed the expression of BRAF protein in 74%, the expression of phospho-EGFR protein in 24% and the expression of phospho-MET in 55%. An association was observed between the increased expression of phospho-EGFR, phospho-MEK, nuclear phospho-p42/44ERK, and total p42/44ERK and the high disease stage (stages III, IV). The genetic alterations observed in the present study (especially the RET/PTC rearrangements and the BRAFV600E mutation) are detected in quite low levels compared to that observed in other populations. They have not been proven to be the major modus of activation in the Greek population harbouring Thyroid cancer. The need of further study of the molecular genetics of the Thyroid cancer in this population is mandatory.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Litsiou, Eleni
- Λίτσιου, Ελένη
Subjects
dc:subject × 23- Θυροειδής αδένας
- Θυλακιοκυτταρικό θυρεοειδικό καρκίνωμα
- Σηματοδοτικό μονοπάτι RAS / RAF / MEK / ERK
- Ελληνικός πληθυσμός
- Θηλώδες καρκίνωμα
- Θυλακιοκυτταρικές θυρεοειδικές καρκινικές κυτταρικές σειρές
- Μοριακές τεχνικές
- Ανοσοϊστοχημεία
- BRAF
- EGFR
- Thyroid
- Thyroid cancer
- Map kinases
- RET / PTCs
- Greek population
- Papillary carcinoma
- Thyroid cancer cell lines
- Molecular techniques
- Immunocytochemistry
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24211